Additionally, CXCR4 overexpression led to mammalian target of rapamycin (mTOR) activation in response to panobinostat treatment in MM cells, suggesting that mTOR pathway activation induces resistance to panobinostat. This evidence concerns the gene CXCR4 and Miyoshi myopathy.